Cagrilintide Results Timeline

What a “cagrilintide results timeline” really describes

Most people who search for a cagrilintide results timeline are picturing something like a week-by-week chart: appetite drops here, the scale moves there, results plateau by some point. That framing fits an approved, widely prescribed drug. Cagrilintide is not that. It is an investigational long-acting amylin analogue, and in 2026 it is not FDA-approved for any use.

That changes what a timeline can honestly be. There is no settled, real-world trajectory drawn from millions of US patients, because cagrilintide isn’t on the market. What exists instead is clinical-trial data — and almost all of the meaningful human weight-loss data is for CagriSema, the once-weekly combination of cagrilintide 2.4 mg and semaglutide 2.4 mg, not cagrilintide on its own.

So when this page describes “the timeline,” it is mostly describing the shape of results seen in the CagriSema trials, with the standalone-cagrilintide contribution called out where the data allows. That distinction matters, because it’s the difference between an accurate expectation and a misleading one.

Note: This page is educational. It describes how results unfolded in published trials. It is not dosing guidance, and cagrilintide is not a drug you can legitimately obtain and self-administer in 2026.

The 68-week arc: the core of the data

The pivotal evidence is REDEFINE 1, a large phase 3 trial in adults with obesity (or overweight plus a weight-related condition) without diabetes. The single most important fact about its timeline is its length: it ran 68 weeks — about sixteen months. That alone reframes expectations. This is not a medication where the headline result lands in a month or two; it’s one where the full effect accumulates over more than a year.

Across that arc, the broad pattern mirrors what’s seen with GLP-1-based therapies generally:

• Early weeks: the appetite and satiety effects begin first. People in trials typically notice reduced hunger and earlier fullness well before the scale reflects much, because the dose is built up gradually rather than started at full strength.
• First few months: weight loss becomes measurable and tends to be steady rather than dramatic, as the body adjusts and the regimen reaches its target level.
• Mid-trial through the back half: the majority of the average loss accrues here, continuing to build rather than flattening early.
• Toward week 68: the average was still climbing for many participants near the end of the trial window, which is part of why these studies run so long.

The widely reported headline from REDEFINE 1 was an average of roughly 22-23% of body weight lost at 68 weeks on CagriSema, versus a small change on placebo. That figure, though, is the combination — and that’s exactly where the standalone-cagrilintide question comes in.

How much of that timeline is cagrilintide alone?

This is the part most “results timeline” content skips, and it’s the most important caveat. REDEFINE 1 didn’t only compare CagriSema to placebo — it also included arms for each component on its own. Reading those arms is what separates an honest cagrilintide page from a hyped one.

The pattern reported was, in plain terms: the combination outperformed semaglutide alone, which in turn outperformed cagrilintide alone. Semaglutide monotherapy landed in the mid-teens percent range over the same 68 weeks; cagrilintide by itself produced clearly less — in the low double digits. The combination’s roughly 22-23% reflected the two mechanisms working together, with amylin-pathway signaling (satiety, slowed gastric emptying) layered on top of GLP-1 effects.

The practical reading: cagrilintide’s own timeline is real but more modest, and the eye-catching numbers people associate with “cagrilintide results” are overwhelmingly the combination’s numbers. Anyone presenting a 20%-plus loss as the expectation for cagrilintide by itself is misreading the data. This is consistent with how cagrilintide is positioned across the research — as an additive component, not a standalone star.

Individual variation: why no single timeline fits everyone

Even within the trials, the average hides wide spread. Some participants lost far more than the mean; others lost much less; some discontinued. A trial average is a useful summary, not a personal forecast. Real trajectories are shaped by starting weight, biology, adherence, how well side effects are tolerated, diet and activity changes, and whether someone stays on treatment for the full period.

There’s also a structural reason individual cagrilintide timelines are uncertain: outside a trial, there is no monitored, dose-titrated, clinician-managed pathway in 2026 to generate one. The clean week-by-week curves come from controlled studies with structured dosing and follow-up — conditions that don’t exist for someone trying to source an unapproved compound independently.

The access reality that caps the timeline

A results timeline is only meaningful if there’s a legitimate way to follow it, and for cagrilintide there currently isn’t. As of 2026 it remains investigational and not FDA-approved. It cannot be legally prescribed off-label or compounded for individuals in the US, because lawful compounding pathways generally require an approved reference product or a recognized basis that cagrilintide does not have on its own.

CagriSema, the combination, was submitted to the FDA in December 2025, with a regulatory decision expected later in 2026. That timing — and whether it’s approved at all — is not guaranteed. Standalone cagrilintide has no separately announced US approval path. So the honest “when can I start a timeline” answer is: not yet, and not through any solo route. The only setting where a real, supervised cagrilintide timeline currently exists is an active clinical trial.

This is why we don’t pair this page with any sourcing or dosing detail. A printed schedule would imply a path to follow it that doesn’t legitimately exist, and applying trial-shaped numbers to an unverified gray-market vial of unknown concentration is unsafe regardless of how “standard” a number looks.

How cagrilintide’s timeline compares to its neighbors

Putting it next to the compounds people cross-shop helps set expectations honestly:

• Versus semaglutide: semaglutide is approved, available, and has a real-world timeline you can actually pursue with a prescription. Cagrilintide does not — its data lives inside CagriSema and trials.
• Versus the combination (CagriSema): the combination is where the strongest numbers come from. Cagrilintide alone is the smaller contributor.
• Versus newer investigational agents like retatrutide: all sit in the “promising trial data, not a solo option” category, and all deserve the same caution about treating trial timelines as personal plans.

If you want a timeline you can act on today, the realistic options are the approved medications — not cagrilintide.

Bottom line on the timeline

The best cagrilintide timeline data is the 68-week REDEFINE 1 trial of CagriSema: a slow, year-plus build to an average of roughly 22-23% body-weight loss, with cagrilintide alone contributing clearly less than the combination headline implies. Individual results vary widely, and — most importantly — cagrilintide is not an approved or legally obtainable drug in 2026, so this timeline describes trial findings, not a treatment plan you can start on your own. Watch the CagriSema FDA decision expected later in 2026 for whether a legitimate, prescribable version of this pathway becomes available, and treat any standalone-cagrilintide protocol you find online as unverified and unsafe.

This reflects US regulatory status as of June 2026 and may change.